Hans W. Nijman - Concepedia

Author

Hans W. Nijman

University Medical Center Groningen ORCID

Also Known As

B. van Triest, H Nijman, H W Nijman, H. Nijman, H. W. Nijman, H.W. Nijman, Hans W. Nijman, Hans Nijman, Hans W Nijman, Hans W. Nijman

423

Publications

22.8K

Citations

H-Index

117

Concepts

All Affiliations

University Medical Center Groningen University of Groningen Leiden University Medical Center University Medical Center Utrecht Institut Gustave Roussy

About

Hans W. Nijman is an author at University Medical Center Groningen specializing in medicine, oncology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	35	70	9.5K
2	Public Health	7	7	357
3	Health Sciences	4	4	731
4	Natural Sciences	1	1	3.4K
5	Nursing	1	1	35

Hans W. Nijman

161

Publications

18.5K

Citations

H-Index

Page 1

	Year	Citations
B lymphocytes secrete antigen-presenting vesicles. Graça Raposo, Hans W. Nijman, Willem Stoorvogel, The Journal of Experimental Medicine Protein SecretionSecrete Antigen-presenting VesiclesHumoral ResponseImmunologyExtracellular Microvesicles	1996	3.4K
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up Nicoletta Colombo, Carien L. Creutzberg, Frédéric Amant, Annals of Oncology Gynecological SurgeryMedicineGynecologyEndometrial CancerOncology	2015	1.4K
Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts Ellen Stelloo, Remi A. Nout, Elisabeth M. Osse, Clinical Cancer Research	2016	819
Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy Alicia León‐Castillo, Stephanie M. de Boer, Melanie Powell, Journal of Clinical Oncology	2020	777
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial Stephanie M. de Boer, Melanie Powell, Linda Mileshkin, The Lancet Oncology	2018	599
Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative Ellen Stelloo, Tjalling Bosse, Remi A. Nout, Modern Pathology Targetable PathwaysTransportec InitiativeHigh-risk Endometrial CancerMedicineCancer Management	2015	476
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial Stephanie M. de Boer, Melanie Powell, Linda Mileshkin, The Lancet Oncology	2019	432
Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer Ninke Leffers, Marloes J.M. Gooden, Renske A. de Jong, Cancer Immunology Immunotherapy	2008	397
<i>POLE</i> Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer Inge C. van Gool, Florine A. Eggink, Luke Freeman-Mills, Clinical Cancer Research	2015	307
Quality of Life After Pelvic Radiotherapy or Vaginal Brachytherapy for Endometrial Cancer: First Results of the Randomized PORTEC-2 Trial Remi A. Nout, Hein Putter, Ina M. Jürgenliemk‐Schulz, Journal of Clinical Oncology Quality Of LifeSurgical OncologyRadiation TherapyMedicineCancer Management	2009	269

Page 1